- Home
- PMTS vs TNGX Comparison
PMTS vs TNGX Comparison
Compare PMTS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMTS
- TNGX
- Stock Information
- Founded
- PMTS 2007
- TNGX 2014
- Country
- PMTS United States
- TNGX United States
- Employees
- PMTS N/A
- TNGX N/A
- Industry
- PMTS Finance Companies
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PMTS Finance
- TNGX Health Care
- Exchange
- PMTS Nasdaq
- TNGX Nasdaq
- Market Cap
- PMTS 274.1M
- TNGX 351.2M
- IPO Year
- PMTS 2015
- TNGX N/A
- Fundamental
- Price
- PMTS $21.49
- TNGX $5.88
- Analyst Decision
- PMTS Strong Buy
- TNGX Strong Buy
- Analyst Count
- PMTS 4
- TNGX 6
- Target Price
- PMTS $36.75
- TNGX $12.20
- AVG Volume (30 Days)
- PMTS 53.7K
- TNGX 2.6M
- Earning Date
- PMTS 08-04-2025
- TNGX 08-06-2025
- Dividend Yield
- PMTS N/A
- TNGX N/A
- EPS Growth
- PMTS 1.33
- TNGX N/A
- EPS
- PMTS 1.58
- TNGX N/A
- Revenue
- PMTS $491,426,000.00
- TNGX $40,990,000.00
- Revenue This Year
- PMTS $14.61
- TNGX N/A
- Revenue Next Year
- PMTS $12.49
- TNGX N/A
- P/E Ratio
- PMTS $13.91
- TNGX N/A
- Revenue Growth
- PMTS 12.81
- TNGX 10.09
- 52 Week Low
- PMTS $18.46
- TNGX $1.03
- 52 Week High
- PMTS $35.19
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- PMTS 42.08
- TNGX 73.28
- Support Level
- PMTS $21.46
- TNGX $5.75
- Resistance Level
- PMTS $23.41
- TNGX $6.40
- Average True Range (ATR)
- PMTS 0.76
- TNGX 0.50
- MACD
- PMTS -0.21
- TNGX -0.03
- Stochastic Oscillator
- PMTS 14.36
- TNGX 83.80
About PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.